MedTrace Logo

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

NCT00242372 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2009-04-22

No results posted yet for this study

Summary

This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized, double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up. Patients must receive at least 30 units of insulin per day and will continue their current oral antidiabetic treatment regimen throughout the study.

Conditions

Interventions

DRUG

Tesaglitazar 0.5

DRUG

Insulin at least 30 units/day

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Galida Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242372 on ClinicalTrials.gov